Sign in Create account

Advanced Enzyme Technologies Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ADVENZYMES BSE: 540025
₹281.60
▼ -0.55 (-0.19%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
66/100
Moderate
Valuation
41/100
Fairly Valued
Momentum
11/100
Bearish

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹3,153 Cr
PE (TTM)
39.3
Industry median 36.1 (152 companies)
Price to Book
1.9
PEG (TTM)
-1.5
Institutions holding %
31.49%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
-4.5
Relative return vs Sector, qtr %
-10.5
Free Cash Flow
₹105 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-69.74%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-26.68%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
13.60%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-69.79%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-7.33%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
9.78
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.01
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
556.07
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
19.29%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
25.70%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
23.94%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
9.44%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
13.58%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
10.31%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.01)
  • No Return on equity is 15% or more (10.3%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.2%
Low 280.2500 · High 287.5000
1W return
-5.2%
Low 279.7500 · High 300.0500
1M return
-4.3%
Low 279.7500 · High 311.0000
52W return
-15.1%
Low 251.9500 · High 419.0000
Lifetime High ₹2352.7500 (Oct. 25, 2016)
Lifetime Low ₹99.5000 (March 23, 2020)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
285.3
10D
288.3
20D
291.9
50D
302.2
100D
310.4
200D
313.0

Delivery and volume

Day avg. delivery
54.5%
Week avg. delivery
58.8%
Month avg. delivery
57.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

283.12
Pivot
First resistance285.98
Second resistance290.37
Third resistance293.23
First support278.73
Second support275.87
Third support271.48
Day RSI34.1
Day MFI43.0
Day MACD-4.88
Day MACD signal-4.37

Beta

1M1.09
3M0.74
1Y1.03
3Y0.90

Price change analysis

↓ -4.3%
Over 1 Month
LowHigh
279.75311.00
↓ -10.5%
Over 3 Months
LowHigh
279.75343.00
↑ 5.7%
Over 6 Months
LowHigh
260.00419.00
↓ -15.1%
Over 1 Year
LowHigh
251.95419.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 39.3 (own history: 21.7–42.9)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹116 Cr
Net profit (June 30, 2026)
₹22 Cr
Basic EPS (June 30, 2026)
₹2.0000

Ranks #70 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter43.24%
  • Mutual funds1.82%
  • FII/FPI26.71%
  • Other DII2.96%
  • Public25.27%

Largest holders

NameCategoryShares %Shares
Vasant RathiPromoter26.6800%29871702
Orbimed Asia III Mauritius FVCI LimitedPublic12.0600%13509522
Nalanda India Equity Fund LimitedPublic8.4500%9465501
Vasant and Prabha Rathi Generation TrustPromoter6.7000%7500000
Polunin Emerging Markets Small Cap Fund, LLCPublic2.4600%2756642

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 43.26% to 43.24% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 25.49% to 26.71% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 1.93% to 1.82% in Jun 2026 qtr

2 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 269 insider trades, 128 SAST, 107 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
2 Apr 2026 Abhijit Kishor Rathi Other Buy 0 ₹0
2 Apr 2026 Ankit Kishor Rathi Other Buy 0 ₹0
2 Apr 2026 Amit Kishor Rathi Immediate relative Buy 0 ₹0
2 Apr 2026 Leela Kishor Rathi Immediate relative Sell 0 ₹0
13 Mar 2026 Vasant Rathi Promoter Buy 0 ₹0
10 Mar 2026 Vasant Rathi Promoter Buy 0 ₹0
10 Mar 2026 Vasant Rathi Promoter Buy 0 ₹0
10 Mar 2026 Vasant Rathi Promoter Buy 0 ₹0
9 Feb 2026 Vasant Rathi Promoter Buy 0 ₹0
7 Feb 2026 Vasant Rathi Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 53 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
29 Aug 2025 POLUNIN EMERGING MARKETS SMALL CAP FUND LLC Bulk Buy 1,250,938 353.5000 NSE
29 Aug 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 1,007,488 352.6100 NSE
29 Aug 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 1,007,488 352.1300 NSE
11 Sep 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 821,877 507.3500 NSE
11 Sep 2024 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 821,877 507.0800 NSE
19 Jun 2024 ORBIMED ASIA III MAURITIUS LIMITED Block Sell 11,053,245 385.0000 NSE
19 Jun 2024 MOTILAL OSWAL FINANCIAL SERVICES LIMITED Block Buy 11,053,245 385.0000 NSE
19 Jun 2024 ORBIMED ASIA III MAURITIUS LIMITED Bulk Sell 11,053,245 385.0000 NSE
19 Jun 2024 MOTILAL OSWAL FINANCIAL SERVICES LIMITED Bulk Buy 11,053,245 385.0000 NSE
19 Jun 2024 ORBIMED ASIA III MAURITIUS LIMITED Block Sell 11,053,245 385.0000 NSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
8 Aug 2026 Buyback —
8 Aug 2026 Financial Results Yes
9 May 2026 Financial Results/Dividend Yes
31 Jan 2026 Financial Results Yes
12 Nov 2025 Financial Results Yes

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 Company Update Advanced Enzyme Technologies Ltd - 540025 - Disclosure Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (As Amended)
28 Sep 2026 Insider Trading / SAST Advanced Enzyme Technologies Ltd - 540025 - Closure of Trading Window
10 Sep 2026 Company Update Advanced Enzyme Technologies Ltd - 540025 - Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Sep 2026 Company Update Advanced Enzyme Technologies Ltd - 540025 - Corporate Action-Updates on Buy back
5 Sep 2026 Company Update Advanced Enzyme Technologies Ltd - 540025 - Disclosure Under Regulation 31A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (As Amended)

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.01)
  • Comfortable interest coverage (556.1x)

Weaknesses

  • Declining revenue YoY (-7.3%)
  • Declining profit YoY (-69.8%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (39.3) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Advanced Enzyme Technologies Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.